Background {#Sec1}
==========

Despite the advances in the field of interventional cardiology, coronary bifurcations lesions, which represent approximately 15--25% of percutaneous coronary interventions (PCI) cases, are still a challenge \[[@CR4]\].

Bioresorbable vascular scaffolds (BVS), which dissolve after fulfilling their support function have been a perennial aim and their introduction to the field of interventional cardiology represented a revolution and hope for vascular reparative therapy \[[@CR8]\].

The Absorb BVS (Abbott Vascular, Santa Clara, CA, USA) is a fully bioresorbable scaffold where the resorption process progresses gradually, mainly secondary to hydrolysis creating minimal or no inflammation. One of the major limitations of the BVS is the 157 microns strut thickness \[[@CR14]\] which make it bulky .

It is reasonable to expect that the theoretical advantages of BVS over metallic drug eluting stents (DES) are to be more pronounced in the subset of coronary bifurcation lesions. Several reasons make us believe in this conclusion; first, arterial healing is faster with the BVS than DES especially if a 2 stent technique was used. Second, late luminal enlargement is secondary to BVS degradation. Third, jailing of the SB is no longer permanent thanks to the resorption of the BVS \[[@CR15]\].

Provisional approach remains the gold standard for percutaneous treatment of patients with unselected bifurcated lesions even when the use of BVS is intended \[[@CR1]\].

Side branch (SB) management is still a challenge. The use drug-coated balloon (DCB) for addressing such an issue may prove advantageous as compared to regular balloon angioplasty \[[@CR10]\].

Our aim in this study was to evaluate the performance of BVS and DCB in bifurcation lesions at midterm follow-up in order to gain a better understanding of their efficacy and safety at this clinical setting.

Methods {#Sec2}
=======

The study is a retrospective study where patients were enrolled from 6 Italian centers over the period from July 2013 to July 2017 with at least 6 months follow-up after the index procedure of the last patient to the maximum available follow-up. The study included all consecutive cases of coronary bifurcations managed or attempted with:

\(a\) The implantation of at least one Absorb BVS in the main vessel.

\(b\) The use of one or more DCB in the side branch.

Exclusion criteria {#Sec3}
------------------

Cardiogenic shockSevere renal impairment (creatinine clearance \< 30 ml/min) or dependence on dialysis.Contraindication to prolonged dual antiplatelet therapy.

Clinical data, including age, sex, risk factors (hypertension, diabetes, dyslipidemia, smoking and family history) and history (previous MI, previous PCI, previous bypass surgery, cerebrovascular disease CABG) was thoroughly obtained. The clinical indication (chronic stable angina, unstable angina, STEMI, or NSTEMI) was also included in the study. Renal function was withdrawn and transthoracic echocardiography was performed in all patients.

The PCI procedural details were also recorded including type of bifurcation lesion (according to Medina classification) \[[@CR12]\], Syntax score, intravascular imaging, balloon predilation, BVS, and DCB used and balloon postdilatation.

Follow-up at the maximum available timing with a minimum of 6 months was done for major adverse cardiovascular events including death, non-fatal MI, scaffold thrombosis, and cerebrovascular stroke.

Results {#Sec4}
=======

Forty patients fulfilled the enrollment criteria, 22.5% had diabetes and 50% an acute coronary syndrome at presentation. The demographic and clinical characteristics of the patients enrolled in the study are enlisted in Table [1](#Tab1){ref-type="table"}. Average syntax score was 15.04 ± 7.18, all lesions were de novo, and 27 patients (67.5%) had a type 1,1,1 Medina lesion. Twenty-three lesions (57.5%) involved the proximal left anterior-descending artery/first diagonal branch. Only 32.5% of patients underwent an intravascular imaging-guided angioplasty. Average lesion length was 21.4 mm in the main vessel and 11.5 mm in the SB. MV was always predilated and BVS received a postdilation in 100% of the cases. In 42.5% of the cases, the DCB was used during final kissing balloon inflation, and in no cases, a stent/BVS was required in the SB. Procedural success was achieved in 100% of the cases. The procedural characteristics are enlisted in Table [2](#Tab2){ref-type="table"}. After an average follow-up of 15.5 (± 11.5) months, we observed no MACE with only one case of target vessel revascularization (2.5%) as shown in Table [3](#Tab3){ref-type="table"}. All the DCBs used eluted paclitaxel (Fig. [1](#Fig1){ref-type="fig"}). Table 1Demographic and clinical characteristics of the study groupCriterionBVS & DCB group (*n* = 40)Males34 (85%)Mean age56.9 ± 10.3Hypertension23 (57.5%)DM9 (22.5%)IDDM5(12.5%)Smoking14 (35%)Dyslipidemia22 (55%)CABG1 (2.5%)Prior PCI11 (27.5%)Stroke0%Previous MI7 (17.5%)Creatinine0.92 ± 0.16 mg/dlHB13.3 ± 1.13 md/dlWeight79 ± 12 kgHeight170.9 ± 6.1 cmEjection fraction56.6 ± 5.1Clinical indication Stable angina20 (50%) Unstable angina6 (15%) NSTEMI8 (20%) STEMI6 (15%) Table 2Procedural detailsProcedural detailsBVS & DCB group (*n* = 40)Access site Radial32 (80%) Femoral8 (20%) LM diseased1 (2.5%) LAD diseased23 (57.5%) LCX diseased11 (27.5%) RCA diseased8 (20%) Syntax score15.04 ± 7.18Medina class 1,1,127(67.5%) 1,1,00(0%) 1,0,10% 0,1,19 (22.5%) 0,1,01 (2.5%) 1,0,01 (2.5%) 0,1,12 (5%) OCT3 (7.5%) IVUS10 (25%)ACC/AHA A0% B12 (5%) B234 (85%) C4 (10%) Denovo lesions100% ISR0% Thrombus5 (2.5%) CTO6 (15%) RVD (proximal MV) (mm)3.13 ± 0.4 Lesion length (MV) (mm)21.42 ± 16.25 RVD SB (mm)2.31 ± 0.34 MLD MV (mm)0.51 ± 0.37 MLD SB (mm)0.77 ± 0.62 Lesion length (SB) (mm)11.49 ± 6.35 % stenosis MV83.2 ± 13.4% % stenosis SB66.79 ± 24% Predilatation MV40 (100%) Predilatation MV balloon diameter2.81 ± 0.45 m Predilatation pressure (atm)13 ± 0.36 Scoring balloon MV1 (2.5%) Rotablator MV0% Type of BVSAbsorb (100%) Length BVS (mm)22.02 ± 6.07 Second BVS used7 (17.5%) Inflation pressure BVS (atm)10.92 ± 1.4 atm Post dilatation of BVS40 (100%) Post dilatation balloon diameter (mm)3.31 ± 0.39 Inflation pressure of postdilatation balloon (atm)20.3 ± 4.4Predilatation SB32 (80%)KB before stent implantation5 (12.5%)Kissing balloon inflation23(57.5%)Predilatation of SB balloon diameter2.25 ± 0.33Predilatation SB balloon inflation pressure11 ± 3 atmType of DCB used Pantera Lux6 (15%) Elutax SV11 (27.5%) Restore6 (15%) Sequent please4 (10%) In.Pact Falcon10 (25%) Danubu1 (2.5%) Agent1(2.5%) Magic1 (2.5%) Diameter of DCB2.43 ± 0.37 mm DCB length20.36 ± 6.42 mm DCB inflation pressure9.4 ± 1.9 atm DCB inflation duration52 ± 10 sec FKB with normal balloons6 (15%) FKB with DCB17 (42.5%) Dissection left after DCB6 (15%)Type of dissections A5 (12.5%) C1 (2.5%)Stenting of SB0%Final % diameter stenosis MB5.3 ± 8%Final % diameter stenosis SB13.0 ± 16.4%Final MLD MB (mm)3.0 ± 0.43 mmFinal MLD SB (mm)1.9 ± 0.5 mmTotal amount of contrast (ml)212 ± 117Procedural time (min)71.8 ± 38 minTotal fluoroscopy time (min)12 ± 3.9 minBVS/DES-related complications0%BVS underexpansion0%Longitudinal deformation0%BVS recoil0%Final TIMI less than 30%Intraprocedural occlusiom0%Intraprocedural death0%Peri-procedural MI0%Medications at discharge Aspirin40(100%) Clopidogrel11(27.5%) Prasugrel4 (10%) Ticagrelor25(62.5%) Table 3Follow-upFollow-up*n* = 40Angiographic follow-up13 (32.5%)Angiographic follow-up indicationStable angina8 (9%)Unstable angina3 (7.5%)STEMI1 (2.5%)NSTEMI1 (2.5%)% diameter stenosis of MV in case of angio follow-up2.9 ± 3.4%% diameter stenosis of SB11 ± 29.49%Average duration from index procedure to the last follow-up (days)444 ± 303Binary restenosis MV0%Binary restenosis SB1 (2.5%)MV MLD3.2 ± 0.47 mmSB MLD1.784 ± 0.6 mmMV TLR0%SB TLR0%Aspirin at follow-up40 (100%)P2Y12 inhibitors at follow-up25 (62.5%)Death0%CV death0%Non CV death0%TV MI1 (2.5%)TV MI managementPOBATLR0%TVR1(2.5%)Date of TVR10-4-2014TLR or TVR managementPOBATL thrombosis0% Fig. 1**a**, **b** Bifurcation lesion involving the ostia of the LCX and RI. **c** After deployment of the BVS. **d** Kissing balloon inflation with DCB. **e** Final result at the index procedure. **f** At follow-up after 25 months

Discussion {#Sec5}
==========

The BVS was expected to represent fourth revolution in interventional cardiology as it offers a new technology by transient scaffolding the vessel and eluting an antiproliferative drug \[[@CR13]\].

Cohort B study, which tested the second generation of BVS, showed a MACE rate of 9.0% \[[@CR17]\]. The follow-up after 3 years in ABSORB II revealed a higher rate of target lesion failure (TLF) in the BVS group (7%) \[[@CR6]\].

A safety alert was issued after Food and Drug Administration (FDA) reviewed the 2-year data from the ABSORB III trial showing a rate of 11% in major cardiac events in patients treated with BVS in comparison to a rate of 7.9% in patients treated with Everolimus eluting stent (EES) \[[@CR16]\].

Thrombosis was the key limitation of the BVS. This was very evident in the Absorb II trial. Specifically, 6 events occurred beyond the first year. The analysis of the 6 cases showed that the main reasons of such events were very late scaffold thrombosis and undersized scaffolds \[[@CR3]\].

Amsterdam Investigator-Initiated Absorb Strategy All-Comers Trial (AIDA) found that there was no significant difference in the rate of target-vessel failure (TVF) between the BVS group and the stent group. There was a higher incidence of device thrombosis with BVS throughout the 2-year follow-up period \[[@CR20]\].

Optimal management for BVS failure is still a topic for research. Different coronary devices were used to address this issue. Restenosis was successfully managed by percutaneous balloon angioplasty (POBA) and DCB \[[@CR11]\] \[[@CR7], [@CR9]\].

The FDA recommended the *PSP* technique for BVS implantation. This technique includes 3 steps: the first step is the lesion preparation with a 1:1 balloon-to-artery ratio using a non-compliant balloon. The second step is the appropriate sizing of the vessel with liberal use of intravascular imaging or quantitative coronary angiography (QCA). The third step is the postdilatation to high pressure using a non-compliant balloon up to 0.5 mm above nominal scaffold diameter. The operators were also advised to use the BVS in vessels with a reference diameter of ≥ 2.5 mm and ≤ 3.75 \[[@CR18]\].

There are a number of advantages in DCBs make them of great use in SB management in the setting of bifurcation PCI. First, the homogeneous administration of the drug; second, high concentrations of drug are delivered into the vessel wall at the moment of injury; third, original anatomy of the carina is respected \[[@CR2]\].

Early experiences have shown how leaving a dissection after plain old balloon angioplasty was associated with increased rates of thrombotic events, early reocclusion, and recurrence of restenosis, and this was one of the main indications for the use of stents in an earlier era. Paclitaxel, when correctly delivered to the vessel wall, may have a role in facilitating the healing of coronary vessels. If the dissection is of low-medium grade, it seems safe to leave it untreated. In fact, data from the literature show how any stent strategy associated with DCB use is unsafe or yields unsatisfactory results. In a consecutive series of patients treated with new-generation DCB for native coronary artery disease and with a final non-flow-limiting dissection, these lesions tended to heal despite their initial severity. After DCB angioplasty, a strategy of bailout stenting should be reserved to more severe, flow-limiting dissections, and in our study, all the dissections were non-flow-limiting, so no DES were needed \[[@CR5]\].

In the time-varying outcomes with the absorb bioresorbable vascular scaffold during a 5-year follow-up: a systematic meta-analysis and individual patient data pooled study {#Sec6}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Target lesion failure occurred in 11.6% of BVS-treated patients vs 7.9% of EES-treated patients between 0 and 3 years (HR, 1.42; 95% CI, 1.12--1.80), and 4.3% of BVS-treated patients vs 4.5% of EES-treated patients between 3 and 5 years (HR, 0.92; 95% CI, 0.64--1.31) (*P* for interaction = .046). Device thrombosis occurred in 2.4% of BVS-treated patients vs 0.6% of EES-treated patients between 0 and 3 years (HR, 3.86; 95% CI, 1.75--8.50) and 0.1% of BVS-treated patients vs 0.3% of EES-treated patients between 3 and 5 years (HR, 0.44; 95% CI, 0.07--2.70) (*P* for interaction = .03). This study shows that despite the worse performance of the BVS as regards TLR and scaffold thrombosis over 0--3 years, their performance was non-inferior to DES or even better as regards TLR and thrombosis over 3--5 years. This gives a hope for the return of the BVS to routine clinical practice after overcoming the technical and procedural issues that influence its safety and efficacy \[[@CR19]\].

The idea of "leaving nothing behind" after PCI is a very exciting concept in modern interventional cardiology especially in bifurcation lesions. This dream started to come true with the introduction of BVS and DCB to the field of interventional cardiology which are still understudied and they open the door for further research in these technologies.

Conclusion {#Sec7}
==========

Our knowledge about the BVS and DCB technology is still growing. However, as it occurred with the first generation of DES, we are still learning how to appropriately use the BVS.

Management of coronary bifurcation lesions with the use of newer technologies including BVS and DCB was found to be feasible and effective at mid-term and long-term clinical follow-up with the implementation of proper implantation techniques.
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